Pradžia › Opinis kolitas › Utah
Opinis kolitas klinikiniai tyrimai Utah
7 tyrimai dėl Opinis kolitas ieško dalyvių vietose Utah.
Miestai Utah
Oficialus tyrimo tekstas (anglų kalba)
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Care Access-Ogden, Ogden
- Advanced Research Institute - South Ogden, Ogden
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-30 · NCT06598943A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- University of Utah Hospitals & Clinics, Salt Lake City
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT06979336A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- University of Utah, Salt Lake City
Renkami dalyviai3 fazė
Amžius 3 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06663332LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Care Access - Ogden, Ogden
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07186101A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- University of Utah Health, Salt Lake City
Renkami dalyviai4 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-21 · NCT06095128An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Velocity Clinical Research, Salt Lake City - Site Number: 8400147, West Jordan
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-08-20 · NCT07184996Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Utah Health, Salt Lake City
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-07 · NCT05230173Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.